Clinical trials: Ovarian Carcinoma
Ovarian Cancer
Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer
The purpose of this study is to evaluate the effect of OPT-822/OPT-821 on improving Progression-Free Survival (PFS) in subjects who have non-progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer after…
- Trial name
- NCT02132988
- Testing
- OPT-822/OPT-821
- Where
- Taiwan
- Volunteers
- 110 people
- Sponsor
- Mackay Memorial Hospital
Ovarian Tumors
First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.
The study consists of two parts based on the administration of single-agent GRN-300 or in combination with paclitaxel. Part 1 (Phase IA) will test the tolerability of continuous twice a day dosing of oral GRN-300, a…
- Trial name
- NCT04711161
- Testing
- GRN-300, Paclitaxel
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Green3Bio, Inc.
Platinum-resistant Ovarian Cancer
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
At present, the standard treatment for platinum-resistant ovarian cancer patients is platinum-free chemotherapy, with poor efficacy and tolerance.
- Trial name
- ANNIE (NCT04376073)
- Testing
- Niraparib, Anlotinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Jihong Liu
Ovarian Clear Cell Carcinoma
Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100
To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma
- Trial name
- NCT06065462
- Testing
- Dostarlimab, LB-100
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Cancer, Ovarian Cancer
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced…
- Conditions
- Advanced Cancer, Ovarian Cancer, Lung Cancer, Colon Cancer
- Trial name
- NCT04354246
- Testing
- Dose escalation: COM902 monotherapy., Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE), Cohort expansion: COM902 (RDFE) monotherapy.
- Where
- 9 sites in United States
- Volunteers
- 94 people
- Sponsor
- Compugen Ltd
Ovarian Cancer, Neoplasms, Ovarian
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer.
- Trial name
- NCT00316173
- Testing
- topotecan, CARBOPLATIN
- Where
- 22 sites in United States, Canada
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Ovarian Cancer
This observational study will collect data about safety in female patients with advanced ovarian epithelial cancer with measurable residual disease after surger y.
- Trial name
- NCT02151370
- Where
- El Salvador
- Volunteers
- 3 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer
This is a clinical trial for women with newly diagnosed ovarian cancer. The purpose of this study is to determine if the addition of a drug called azacitidine (Vidaza®)when added to carboplatin and paclitaxel will change the…
- Trial name
- NCT00842582
- Testing
- Azacitidine
- Where
- 2 sites in United States
- Sponsor
- Loyola University
Hereditary Breast and Ovarian Cancer Syndrome
Trial of Inquiry Based Stress Reduction (IBSR) Program for BRCA1/2 Mutation Carriers
Breast cancer (BC) is a major health problem and the most prevalent cancer among women.In a substantial proportion of familial cases, germ-line mutations in either BRCA1/2 can be detected.
- Trial name
- NCT01367639
- Testing
- Inquiry Based Stress Reduction (IBSR) program
- Where
- Israel
- Volunteers
- 67 people
- Sponsor
- Sheba Medical Center
Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer
Validation of a Nutrition Screening Tool
The objective of this study is to evaluate the sensitivity and specificity of two nutrition screening tools to identify inpatients with malnutrition or at risk of malnutrition.
- Conditions
- Adenocarcinoma of the Gastroesophageal Junction, Cervical Cancer, Endometrial Cancer, Esophageal Cancer
- Trial name
- NCT01851928
- Where
- United Kingdom
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Royal Marsden NHS Foundation Trust
Ovarian Cancer
Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.
- Trial name
- ORTRAI (NCT07361471)
- Testing
- molecular analysis
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Centre Jean Perrin
Adnexal Mass, Perioperative Complication
Preoperative Care In Ovarian Cancer Patients
A randomised controlled trial study consisting of two-group pretest-post-test.
- Conditions
- Adnexal Mass, Perioperative Complication, Outcome, Fatal
- Trial name
- NCT04260334
- Testing
- Preoperative Education
- Where
- Turkey (Türkiye)
- Volunteers
- 46 people
- Sponsor
- Dokuz Eylul University
Uterine Cervical Neoplasms, Uterine Neoplasms
Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients
The purpose of this study is to evaluate the effectiveness of self-administered perioperative guided imagery to reduce perioperative distress in gynecologic oncology patients undergoing surgical management for a presumed cancer…
- Conditions
- Uterine Cervical Neoplasms, Uterine Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms
- Trial name
- NCT02444195
- Testing
- Guided Imagery With Audio Media
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- University of Michigan
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05281471
- Testing
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Where
- 33 sites in United States
- Volunteers
- 186 people
- Sponsor
- Genelux Corporation
Urinary Bladder Cancer, Melanoma
MAGE-A4ᶜ¹º³²T for Multi-Tumor
This study will investigate the safety and tolerability of MAGE-A4ᶜ¹º³²T cell therapy in subjects who have the appropriate HLA-A2 tissue marker and whose urinary bladder, melanoma, head and neck, ovarian, non-small cell lung…
- Conditions
- Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer
- Trial name
- NCT03132922
- Testing
- Autologous genetically modified MAGE-A4ᶜ¹º³²T cells, Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation
- Where
- 11 sites in United States, Canada
- Volunteers
- 71 people
- Sponsor
- USWM CT, LLC
Breast Cancer
Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2
RATIONALE: Studying the immune response to a vaccine made from HER2/neu protein may help doctors plan better treatment for patients with breast cancer that overexpresses HER2.
- Trial name
- NCT00363012
- Testing
- HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- University of Washington
Ovarian Cancer
Fermented Wheat Germ Extract in Women With Ovarian Cancer
The main purpose of this Pilot Study is to test the safety, tolerability and quality of life in women who take Fermented Wheat Germ Extract (FWGE), to determine if an active form of FWGE can be detected in the blood, and…
- Trial name
- NCT02411565
- Testing
- Fermented Wheat Germ Extract (FWGE), Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Ovarian Cancer
Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse
Determination of progression free survival after 12 months of FU Determination of total survival, response and quality of life
- Trial name
- HECTOR (NCT00437307)
- Testing
- Topotecan
- Where
- Germany
- Volunteers
- 550 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Advanced Stage Serous Epithelial Cancer of the Ovary, Advanced Stage Cancer of Tubes
Impact of Systematic Imaging for Follow up of Patients With Ovarian, Fallopian Tube or Primary Peritoneum Cancer
After well-conducted treatment of ovarian, tubal and primary peritoneum cancer by maximum tumor reduction surgery and chemotherapy including platinum salt and paclitaxel, the clinical remission rate is over 50%.
- Conditions
- Advanced Stage Serous Epithelial Cancer of the Ovary, Advanced Stage Cancer of Tubes, Advanced Stage Cancer of Peritoneum
- Trial name
- QUALOV (NCT04826029)
- Testing
- Standard strategy, Follow-up strategy
- Where
- France
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cervical Cancer, Fallopian Tube Cancer
Immunotoxin Therapy in Treating Patients With Advanced Cancer
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be an effective treatment for advanced cancer.
- Conditions
- Cervical Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer
- Trial name
- NCT00006981
- Testing
- SS1(dsFv)-PE38 immunotoxin
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.